secwatch.observer — SEC 8-K summary
======================================

Issuer:     REGENXBIO Inc. (RGNX)
CIK:        0001590877
Form:       8-K
Filed at:   2024-09-17T23:59:59+00:00
Accession:  0000950170-24-107367
Event type: leadership
Sentiment:  neutral
Materiality: 0.70
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

REGENXBIO appoints Mitchell Chan as CFO; Vittal Vasista steps down after 15 years
--------------------------------------------------------------------------------

- Mitchell Chan appointed EVP, CFO effective Sept. 16, 2024; base salary $490K, 40% bonus target, $3M equity grant (75% options, 25% RSUs).
- Vittal Vasista resigns after 15+ years; separation allowance $500,018 over 3 installments and up to 75% of 2024 targeted bonus.
- Vasista will serve as advisor to CEO through Jan. 3, 2025; unvested equity forfeited after advisory period.
- Chan brings 20 years biopharma finance experience; prior CFO of Viela Bio (led $3B Horizon acquisition) and operating partner at Catalio.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1590877/000095017024107367/0000950170-24-107367-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1590877/000095017024107367/rgnx-20240916.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-107367

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer